Treatment of Refractory or Resistant CMV
This conference is being held virtually.
This course is intended for pharmacists.
At the completion of this activity, the participant will be able to:
- Recognize cytomegalovirus, its prevalence in solid organ transplant and HSCT patients, and standard-of-care treatments associated with prevention and treatment of diseases.
- Evaluate current guidelines and primary literature examining the utilization of letermovir and maribavir for the prevention and treatment of CMV, including refractory and resistant CMV.
- Apply knowledge and design treatment plans for patients who have high-risk refractory or resistant CMV.
Karishma Desai, Pharm.D. - PGY-2 Infectious Diseases Resident at Advocate Christ Medical Center
The planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose.
1 contact hour of continuing pharmacy education (1.00 CEU) is available for pharmacist participants.
- 1.00 Continuing Pharmacy Education (CPE)Aurora Health Care Department of Pharmacy Services is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Click “Take Course” to register for this program.
This conference is being held virtually. A link to the meeting will be provided prior to the event.
Contact the AAH Pharmacy Continuing Education team at AAH-PharmacyCPEsubmission@aah.org if you have any questions or need assistance.